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The present study was planned to investigate the influence of polyethylene glycols (PEGs) on the 
activity and expression of P-glycoprotein (P-gp). Sub-toxic concentrations of PEGs in Caco-2 cells were 
determined using the MTT test assay. Then the measurement of Rhodamine-123 (Rho-123) uptake, a 
P-gp fluorescence substrate, in Caco-2 cells confronting PEG 400 (1% and 2% w/v), PEG 4000 (2% and 
4% w/v), PEG 6000 (2% and 4% w/v), PEG 10000 (2% and 4% w/v), PEG 15000 (1% and 2% w/v), 
and PEG 35000 (2% and 4% w/v) overnight was taken to elucidate whether non-toxic concentrations of 
PEGs are able to impact P-gp activity. Furthermore, western blotting was carried out to investigate P-gp 
protein expression. The results showed that PEG 400 at concentrations of 1% (w/v) and 2% (w/v) and 
PEG 6000 at the concentration of 4% (w/v) are notably capable of blocking P-gp. Based on the obtained 
results it is concluded that the mentioned excipients could be used to obstruct P-gp efflux transporter in 
order to increase the bioavailability of co-administered substrate drug.
Uniterms: P-glycoprotein/activity. P-glycoprotein/expression. Caco-2. Rhodamine-123. Excipients. 
Drugs/bioavailability. Polyethylene glycol/effects.
O presente estudo foi planejado para investigar a influência de polietileno glicóis sobre a atividade e expressão 
da P- glicoproteína (P-gp) . Concentrações sub-tóxicas de PGPs e em células Caco-2 foram determinadas 
por meio do ensaio de MTT. Em seguida, efetuou-se a a medida de captura de Rodamina-123 (Rho-123), 
um substrato fluorescente de P-gp, em células Caco-2, confrontando com PEG 400 (1% e 2% m/v), PEG 
4000 (2% e 4% m/v) e PEG 6000 (2% e 4% m /v), PEG 10000 (2% e 4% w/v), PEG 15000 (1% e 2% m/v), 
e PEG 35000 (2% e 4% m/v). Essa medida foi efetuada durante a noite, para saber se as concentrações 
não tóxicas de excipientes são capazes de influenciar a actividade da P-gp. Além disso, realizou-se o 
western blotting para investigar a expressão da proteína P-gp. Os resultados mostraram que o PEG 400, 
nas concentrações de 1% (m/v) e 2% (m/v), e PEG 6000, na concentração de 4% (m/v) são capazes de 
bloquear P-gp. Com base nos resultados conclui-se que os excipientes mencionados poderiam ser utilizados 
para obstruir o efluxo por P-gp, a fim de aumentar a biodisponibilidade de do fármaco co-administrado.
Unitermos: Glicoproteína-P/atividade. Glicoproteína-P/expressão. Caco-2. Rodamina-123. Excipientes. 
Fármacos/biodisponibilidade. Polietilenoglicol/efeitos.
INTRODUCTION
While oral drug administration has many preferable 
characteristics, like intensified patient compliance and 
easier chronic administration as compared with other 
pharmaceutical forms, nearly 50% of orally taken drugs 
bioavailability (BA) is declined owing to their poor and 
inadequate absorption through intestinal mucosa (Gursoy, 
Benita, 2004; Shah et al., 2013).
Membrane bound transport systems are one of 
the physiological factors that impact the intestinal 
absorption of drugs and therefore could be essential 
in drug pharmacokinetics and disposition alteration in 
the body. Among these transporters, P-gp, prevalently 
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distributed in small intestine, is a crucial transporter 
responsible for the efflux of drugs and it is assumed that 
P-gp is implicated in cell detoxification (Hayeshi et al., 
2006; Simon, Schubert, 2012). P-gp is an ATP-dependent 
product of multi drug resistance gene in human, which is 
ligand for various substrates from drugs such as verapamil 
(Bellamy, 1996), cyclosporine A (Simon, Schubert, 2012), 
vinca alkaloids (Arora, Shukla, 2003), anthracyclines, 
cardiac glycosides (Sababi, Borga, Hultkvist-Bergtsson, 
2001), vinblastine (Shirasaka et al., 2006), venlafaxine 
(Ehret et al., 2007), R-cetirizine (Shen, He, Zeng, 
2007), etoposide (Parsa et al., 2013), quinidine (Fromm 
et al., 1999), and immunofluorescent dyes such as 
Rhodamine-123 (Pétriz, García-López, 1997). Moreover, 
it is believed that drugs such as dexamethasone, rifampicin 
and some chemotherapeutic agents such as doxorubicin, 
daunorubicin and vinblastine are able to induce P-gp 
expression.
P-gp induction is of considerable concern because 
it can significantly decrease the BA of substrate drugs. In 
the case of intestinal drug absorption, expression of P-gp 
can attenuate BA of drugs, which are substrate for P-gp. 
In a study, co-administration of Rheum palmatum, a P-gp 
inducer, and phenytoin predominantly decreased the oral 
BA of phenytoin because it initiated P-gp expression (Chi 
et al., 2012). Additionally, P-gp is considered to overexpress 
in neoplastic cells. Resistance to chemotherapy is prevalent 
among treatments and it is attributed to P-gp. It is assumed 
that P-gp is responsible for cancer treatment failings and it is 
a major obstacle in chemotherapies. For example, in a study, 
a P-gp blocker was able to increase paclitaxel concentration 
in blood (Kang et al., 2001). In addition, Compound K, the 
major component obtained from ginsenosides metabolism 
which is being used in treatment of lung cancer, showed 
reduced plasma Cmax and AUC0–24h when P-gp was inhibited 
(Yang et al., 2012).
On the other hand, some studies refused the role 
of P-gp in drug efflux. For example, in an experiment 
performed by Dickens et al., hypothesis claiming that P-gp 
is overexpressed at the epileptic focus was rejected as anti-
epileptic drugs like carbamazepine and lamotrigine were 
proven not to be substrate for P-gp (Dickens et al., 2013).
P-gp acts as a barrier for orally used drugs. By 
restricting the absorption of drugs through intestine, P-gp 
is involved in the causation of low BA of some drugs. 
Due to this fact, components, which are P-gp function/
expression inhibitors have prominent role in exceeding 
drug BA and there is an increasing interest in enhancing 
BA of drugs by inhibiting intestinal P-gp. Reportedly, 
some synthetic phospholipids and several pharmaceutical 
excipients may have the potential to modulate this 170 
kDa protein, P-gp. (Lo, 2000; Wandel, Kim, Stein, 2013)
Excipients are material used in drug formulations 
alongside the active compound. They were believed to be 
an inactive part of a drug formulation; however, studies 
demonstrated that excipients are not inert and they can have 
subtle effects on absorption or elimination of concomitant 
drugs administered (Buggins, Dickinson, Taylor, 2007). 
Many attempts have been made to evaluate the capability 
of excipients to augment drug BA. Some excipients, such 
as Vitamin E TPGS (Collnot et al., 2006), nowadays are 
used as a P-gp inhibitor with the aim of increasing the BA 
of co-administered drugs (Guo et al., 2013). In a study 
previously conducted in our lab, we screened the effect of 
tween excipients on P-gp expression and activity in Caco-
2 monolayers. In the current study, we have extended the 
range of excipients tested and PEG excipients were selected. 
PEGs are amphiphilic, non-micelle forming hydrophilic 
polymers of molecular weights, ranging from 200 to 
35000 (Basit et al., 2002). They are commonly used as 
pharmaceutical excipients to raise the aqueous solubility 
of drugs that are poorly soluble in water. Therefore, current 
study was designed to explore whether this subclass 
of nonionic excipients are able to block P-gp at varied 
concentrations. By studying the effect of these excipients 
on both the expression and the activity of P-gp, we aim to 
present a procedure to increase drug BA.
Derived from human colorectal adeno-carcinoma, 
Caco-2 cell monolayer is widely used as a representative 
for human intestinal epithelial cells since it retains 
many features of small intestinal closely mimicking the 
enterocytes of small intestine (Pang, 2003). Caco-2 cells 
express P-gp efflux pump and is a well-established cell line 
to investigate P-gp expression and blockage (Taipalensuu 
et al., 2001).
Consistent with our previous work in which tween 
excipients showed a promising inhibitory effect on the 
expression and activity of P-gp (Hodaei et al., 2013), 
the aim of this work was to investigate the effect of PEG 
excipients on expression and activity of P-gp. Analysis 
of P-gp activity could be performed with an appropriate 
substrate, which is able to give a measurable amount when 
P-gp is blocked. To this aim, we utilized Rho-123, which is a 
fluorescence substrate of P-gp and an ideal probe to explore 
the effects of excipients on P-gp expressed by Caco-2 cells. 
Accumulation of Rho-123 in Caco-2 cells were examined 
both quantitatively and qualitatively; moreover, to elucidate 
the effects of excipients on P-gp expression, western 
blotting was conducted. In both experiments, verapamil 
was selected as relative P-gp inhibitor, as it has been used 
in frequent studies of P-gp transportation (Sababi, Borga, 
Hultkvist-Bengtsson, 2001).
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MATERIAL AND METHODS
Material
Human carcinoma colorectal Caco-2 cell line was 
from National cell bank of Iran, Pastur institute. Excipients 
and dimethylsulfoxide (DMSO) were kindly provided 
by Merck, Germany. Trypsin was provided by Gibco, 
Invitrogen, USA. Fetal Bovine Serum (FBS) was obtained 
from Gibco, Invitrogen, USA. RPMI 1640 - Powdered Cell 
Culture Medium was product of PAA Co, Austria. Trypan 
blue was obtained from Biosera, France. Rhodamine 123 
was purchased from Sigma, USA. Anti β-actin antibody 
was supplied from GE, USA. MDR1 antibody (C219) 
was provided from Abcam, Cambridge, UK. X-ray film 
was purchased from Xoe, USA. Total protein assay kit 
was obtained from Pars Azmoon, Iran and all cell culture 
disposable equipment was obtained from Orange, Belgium.
Caco-2 cell line
Caco-2 cells were routinely maintained in culture 
dishes (T75 falcons, Orange, Belgium) at 37 °C in a 
humidified atmosphere incubator containing 5% CO2 
(Memmert, Germany) and maintained in RPMI-1640 
supplement with 10% fetal bovine serum, 1% sodium 
pyruvate, 1% non-essential amino acids and 1% L-alanine-
glutamine 200 mM. Medium was exchanged every 2nd 
day and cells were split when they were approximately 
90% confluent. Then the cells were washed with PBS 
(Phosphate Buffered Saline) and detached with 0.25% 
trypsin and 0.02% EDTA. PBS Solution contains 137 mM 
sodium chloride, 2.7 mM potassium chloride and 10 mM 
phosphate buffer.
MTT test assay 
MTT (3- (4 ,5 -d imethy l th iazo l -2 -y l ) -2 ,5 -
diphenyltetrazoliumbromide) test, as firstly designated by 
Mosmann ( 1983), is a delicate test for discovering acute 
toxicity of materials in an in vitro system on a certain type 
of cells which can determine the toxicity of excipients on 
Caco-2 cells as well.
After detaching from T-75 flasks, cells were 
centrifuged at 1000 rpm for 5 minutes (Behdad, Nabziran 
Inc., Iran). Cells were distributed in 96-well plates by 
placid sucking (15000 cells in each well). The well plate 
was incubated overnight. On the other day, 200 μL of 
different series of excipients were pipetted to each well 
in triplicates. A solution of DMSO was used as positive 
control (viability 0%) and negative control column 
was filled with fresh medium. Cells were incubated 
for 24 hours and on the third day of experiment (after 
48 h cell growing), media were removed from wells 
and cells were washed by PBS (Sachs-Barrable et al., 
2007); subsequently, 50 μL of MTT solution (2 mg/mL) 
(Sigma, St Louis, MO, USA) were added per well and 
after incubating for 4 hours, MTT solution was removed 
and 200 μL DMSO/25 μL Sorensen buffer was added 
to dissolve MTT-formazan crystals. Identification and 
quantification of the formazan crystals was accomplished 
and recorded at 570 nm. All absorbance values calculated 
as a percent of the negative control, were converted to 
viability data and the mean value of three determinations 
was then taken for further calculations (Mohammadzadeh 
et al., 2014). Concentrations which have not killed 90% 
of cells are probably non-toxic to cells and were chosen 
for further investigations (Lonnroth, 2005).
Assessing uptake of rhodamine-123 
For uptake studies, Caco-2 cells were seeded into 
24-well plates (105 cells/well) and left for 24 hours. 
After washing with PBS, cells were exposed to solutions 
containing excipients and incubated for another 24 hours 
at 37 °C. Standard P-gp inhibitor, verapamil was used as a 
positive control. After incubation period, Rho-123 solution 
(RPMI containing 10 mM HEPES (pH=7.4) and 5 μM 
Rho-123) was added and incubated in 37 °C for 3 hours. 
Rho-123 solution was removed and cells were washed three 
times with ice-cold PBS. By addition of 1% Triton X-100 
cells were lysed and centrifuged at 1000 rpm for 5 minutes. 
Supernatant was used to measure the fluorescence and 
total protein content. Quantity of Rho-123 was calculated 
using a fluorescent microscope reader (Jasco, JAPAN, 
excitation wavelength: 485 nm, emission: 530 nm). First 
the calibration curve of Rho-123 for determination of Rho-
123 in samples was created (Absorbance= 5.04Conc + 
2.07, R2=1). After calculating the rhodamine concentration 
in the cells, the cellular Rho-123 accumulation was 
normalized with respect to total protein content determined 
by protein assay kit (Pars Azmoon, Iran), which is based 
on biuret test. Bovine serum albumin was used as standard 
(Mohammadzadeh et al., 2014). 
Western blotting
Caco-2 cells were shifted to plates and treated with 
different concentration of PEGs for 24 hours. Cells were 
washed with PBS and then incubated for 5 minutes with 
Trypsin/EDTA 0.25. Cell sediment was washed with PBS 
and cells were lysed and then centrifuged at 15000 rpm 
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for 5 minutes. Proteins were separated by electrophoresis 
through SDS-polyacrylamide gel on 12.5% running gel and 
4% stacking gel at 80 V for 120 min and then electro blotted 
to polyvinylidenedifluoride (PVDF) membrane using semi-
dry western blotting; membrane was kept in 3% non-fat dry 
milk for 1 hour to be blocked and then was washed 3 times 
with PBS-Tween 20 0.1% and then incubated overnight 
with primary monoclonal antibody (Anti-β-actin), diluted 
1/1000 in PBS containing 0.1% tween 20 to detect actin as 
control. The next day, membrane was washed with PBS-
Tween 20 0.1% and incubated with horseradish peroxidase-
conjugated Rabbit anti-mouse secondary antibody for two 
hours. Enhanced chemiluminescence (ECL) kit solutions 
were added and then membrane was exposed to X-ray film. 
Membrane was washed twice and incubated with MDR1 
Antibody (C219) (Abcam, Cambridge, UK) overnight. After 
washing, membrane was put into horseradish peroxidase-
conjugated Rabbit anti-mouse secondary antibody for two 
hours. Membrane was washed and then solution A and B of 
ECL kit was added, then membrane was exposed to X-ray 
film (Mohammadzadeh et al., 2014).
RESULTS 
MTT test results
Different concentrations of PEG 4000, PEG 6000 
and PEG 10000 showed no toxic effect on caco-2 cells 
while PEG 15000 4% (w/v) and PEG 400 4% (w/v) 
exhibited significant toxic effect on cells as Figure 1 
and Figure 2 indicate. PEG 35000 revealed 88±4% cell 
viability when compared to control well and there was 
no statistical difference between them (p<0.001). MTT 
test assay showed the maximum tolerable dose for each 
excipient on Caco-2 cells which were afterward used 
to treat cells for the P-gp protein expression, Rho-123 
accumulation and transport studies.
However, we know that the number of examined 
concentrations is not sufficient to demonstrate the dose-
dependent manner. In this view, we only speculate that 
there may be such a trend in the effects. Further work is 
needed to confirm this result.
Rho-123 uptake results
All treatments with PEG 400 and PEG 6000 4% 
(w/v) resulted in a remarkable increase in Rho-123 
accumulation with respect to the control as portrayed in 
Figure 3. The Rho-123 accumulation in cells treated with 
PEG 4000, 10000, 15000 and 35000 was not notably 
different from that of control cells (Figure 4). Observing 
cells under Immuno-fluorescent microscope qualitatively 
illustrated that PEG 400 and PEG 6000 (4% w/v) presence, 
subsequently decreased Rho-123 efflux and significantly 
increased intracellular concentrations when compared to 
that of control group (Figure 5).
Western blotting results
P-glycoprotein expression by caco-2 cells was 
investigated after treating cells with PEGs and verapamil. 
FIGURE 2 - Effects of PEG 400, 4000 and 6000 on cell viability 
in Caco-2 cells. MTT assays were performed to measure the 
survival rate of Caco-2 cells after treatment with PEG excipients. 
Data were expressed by the mean of percent cell viability 
compared to control after exposure for 24 hours ± standard 
deviation of at least 3 measurements.
FIGURE 1 - Effects of PEG 10000, 15000, and 35000 on cell 
viability in Caco-2 cells. MTT assays were performed to measure 
the survival rate of Caco-2 cells after treatment with PEG excipients. 
Data were expressed by the mean of percent cell viability compared 
to control after exposure for 24 hours ± standard deviation of at 
least 3 measurements.
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As Figure 6 depicts, among PEGs used in this study, PEG 
400 1% and 2% (w/v) and PEG 6000 4% (w/v) decreased 
the expression of P-gp when compared to control group.
DISCUSSION 
Multidrug resistance (MDR) continues to be a 
challenge in drug delivery since BA of drugs taken orally 
is being changed by many factors among which low 
absorption through intestinal barrier cells is of utmost 
importance. Efflux transporters, such as P-gp, have great 
preventing effect in drug penetration through intestine; 
hence, inhibiting P-gp may be an effective way in boosting 
drug BA. For this purpose, various approaches have been 
employed. For instance, in our previous study Eudragits 
were reported to be P-gp inhibitor and increase the BA 
of co-administered substrate drugs (Mohammadzadeh et 
al., 2014). Moreover the large molecular weight PEGs, 
have been reported to hinder the secretory transport 
(basolateral to apical) of Rho-123 across the isolated rat 
intestinal membranes at concentrations of 0.1 to 20 % 
FIGURE 6 - P-gp protein expression level in caco-2 cells treated 
with PEGs. Expression in groups treated with PEGs were 
compared with P-gp expression in untreated control cells (C).
FIGURE 5 - Photos taken by immunofluorescence microscope 
illustrates higher intercellular accretion of Rho-123 in cells 
treated with excipients when compared to that of control.
FIGURE 4 - Effect of PEGs on Rho-123 uptake across Caco-
2 cells. PEG 400 1% and 2% (w/v) and PEG 6000 4% (w/v) 
enhance Rho-123 uptake into Caco-2 cells. Caco-2 cells 
were pretreated for 24 hours with different concentrations of 
excipients and 0.3 mM verapamil as positive control for P-gp 
inhibition. Data were expressed by the ratio of quantity of 
Rho-123 (mg×106/mL) to total protein (mg/mL) in each well 
(mean±S.E). Statistical analysis was performed with analysis 
of variance (ANOVA) Student-Newman-Keuls post hoc test.
FIGURE 3 - Effect of PEGs on Rho-123 uptake across Caco-2 
cells. Caco-2 cells were pretreated for 24 hours with different 
concentrations of excipients and 0.3 mM verapamil as positive 
control for P-gp inhibition. Data were expressed by the ratio of 
quantity of Rho-123 (mg×106/mL) to total protein (mg/mL) in 
each well (mean±S.E). Statistical analysis was performed with 
analysis of variance (ANOVA) Student-Newman-Keuls post 
hoc test.
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(w/v), reflective of P-gp inhibition (Shen, et al., 2006). 
PEG 20000 20% (w/v), a high molecular weight PEG, 
was also shown to significantly increase the Rho-123 
AUC and intestinal absorption in rat situ closed loop 
model (Shen, et al., 2006). However, in the current study, 
we found no alteration in Rho-123 uptake after treating 
with high molecular PEGs, except for PEG 6000. The 
discrepancy between in vivo and in vitro results was 
also reported in previous studies (O’Brien et al., 2012). 
Therefore, there remains a demand for the development 
of a validated and highly reliable predictive screening 
model for the accurate identification of P-gp substrates 
and inhibitors. Figure 3 shows that out of the six PEGs 
tested only two, PEG 400 1%, PEG 400 2% and PEG 
6000 4%, caused an increase in Rho-123 uptake by 
150%, 170% and 200% respectively while the transport 
of Rho-123 was not affected by other PEGs. We can also 
find a significant difference (p<0.001) between rhodamin 
uptake in the presence of PEG 400 1% and 2%. Therefore, 
dose-dependent manner in the case of PEG 400 could 
be speculated. Moreover the effect of PEG 400 (1% 
and 2%) and PEG 6000 on rhodamin accumulation was 
significantly different (p<0.001) from that of verapamil. 
However, more number of concentrations should be 
examined to confirm these results. No previous studies 
have been conducted on the effect of PEGs 4000, 10000, 
15000 and 35000 on P-gp while there was a study done 
on PEG 300; an excipient, which we did not include in 
our study. Mentioned investigation yielded some data 
on PEG 300 demonstrating that PEG 300 in relatively 
high concentrations is able to modulate P-gp substrate 
drugs such as doxorubicin and taxol across Caco-2 cells; 
moreover, the inhibitory effect of PEG 300 was claimed to 
be concentration-dependent (Hugger, Audus, Borchardt, 
2002a).
In a study reported by Rege et al. (2001)PEG 400 
at the concentration of 1.5%, showed no effect on Caco-2 
cells in transport of cimetidine and furosemide. In another 
study it was demonstrated that PEG 400 was able to 
eminently inhibit P-gp in a dose-dependent manner when 
concentrations above 1% to 20% was tested on excited rat 
intestine (Johnson, Charman, Porter, 2002). Corroborating 
the latter finding, our results showed that PEG 400 was able 
to inhibit both the activity and expression of P-gp in 1% 
and 2% (w/v). Although low molecular weight PEGs like 
PEG 400 could be used in all pharmaceutical formulations, 
they are typically used in parenteral formulations. The 
maximum safe concentration of PEG 400 is considered 
to be 70%. However in parenteral formulations it is 
considered to be relatively safe in concentrations less 
than 30% (Hugger et al., 2002b). Moreover, PEG 400 
was demonstrated to enhance absorption of ganciclovir 
in rats; however, the effect was not as significant as that 
of verapamil (Li et al., 2011). Our study confirms their 
findings in that the accumulation of Rho-123 was less in 
cells treated with PEG 400 than that of cells treated with 
verapamil (200%) which is obvious in Figure 3. Ashiru, 
Patel, Basit, (2008)and Schulz et al.(2003) observed a 
parabolic increase, with the maximum effect at 1% (w/v), 
in ranitidine BA in male subjects when co-administered 
with low doses of PEG 400; however, high doses did not 
affect ranitidine absorption. The current study did not 
support their results and failed to concur with their finding 
because PEG 400 2% (w/v) represented its P-gp inhibitory 
effect even more than PEG 1% (w/v) and there was no 
obvious difference in the expression of P-gp between 
PEG 400 1% and 2% inhibitory effect on P-gp. However 
it should be noted that their studies were conducted in 
vivo, showing the gender-dependent effect of PEG 400 
and also its detrimental effect on drug absorption in high 
concentrations presumably via a reduction in the small 
intestinal transit time. Based on our own observations, 
as can be seen in Figure 3, PEG 400 increased uptake of 
Rho-123 into Caco-2 cells (Hugger et al., 2002b). Figure 
6 shows the effect of PEG 400 on P-gp expression.
The exact mechanism by which P-gp blockage 
occurs in the presence of PEGs is still unknown but there 
are some suggested hypotheses. For example, Ming et al. 
proposed that the increase in the absorption is a complex 
result of P-gp blockage and membrane fluidity (Li et 
al., 2011), similarly, Rege et al. introduced membrane 
fluidity as an important factor in drug BA amended 
by excipients (Rege, Kao, Polli, 2002). Compounds 
that are P-gp substrates are primarily hydrophobic and 
diffuse passively through the membrane. On the other 
hand drug-binding domains of P-gp are present in the 
transmembrane segments. Therefore P-gp will be highly 
sensitive to the lipid environment. It is suggested that 
oxyethylene groups existed in the structure of excipients 
such as PEGs prompts the membrane to change its lipid 
phase and with this mechanism the P-gp breakdown is 
resulted (Hugger et al., 2002b). Shen et al. remarked that 
alkyl and unsaturated C–C bond in the chemical structure 
of PEG derivatives may be essential for interacting with 
P-gp and influence its function (Shen, et al., 2006). Ferte 
et al. (2000) declared that P-gp is highly sensitive to lipid 
environment and membrane lipid phase can change when 
faced with components containing many oxyethylene 
groups so do the fluidity of the polar head group regions 
of the cell membrane  2. However, no general trend has 
been emerged yet. Further studies with more number of 
PEGs concentration levels, in vitro and in vivo, should 
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be conducted to establish a possible trend. It is also 
manifestly demanding to build up a logical concept and 
further biochemical experiments to understand the exact 
mechanism of this alteration.
CONCLUSION
Based on the obtained results PEG 400 1% and 2% 
(w/v) and PEG 6000 4% (w/v) increased Rho-123 uptake 
and decreased P-gp expression. We also conclude that 
PEG 400 and PEG 6000 at mentioned concentrations are 
effective in diminishing P-gp mediated efflux system to 
increase absorption of drugs that are substrate for P-gp 
through intestine.
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